However, in contrast to previous studies, such as the SHARP trial where no biomarker was established to help with the dosing of sorafenib in HCC patients, we used a predefined inclusion of patients based on their serum levels of AFP [19], which is a prognostic covariate in scoring systems such as CLIP [20]. The gene discussed is AFP; the disease is hepatocellular carcinoma.